Clinical trials

#Academic #AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Biomarkers #Business #Cell therapy #Cellular assays #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Enabling technologies #Gene therapy #Genetics / genomics #Genomics #High Content Screening #High throughput screening #Immunology #Lead discovery #Metabolomics #Molecular medicine #Oncology #Precision medicine #Protein chemistry / Proteomics #Regulatory #RNA #Screening #System biology #Systems biology #Target validation #Therapeutics #Translational #Translational chemistry

Biomarker Discovery: The Need For New Generation Peptide-Protein Microarrays

Biomarker Discovery: The Need For New Generation Peptide-Protein Microarrays By Dr Nikolai Schwabe and Katherine Catchpole The progression from health to disease is marked by significant biological changes within an individual (1). Clinically presenting symptoms, however, can be non-specific and variable enough to… Read More

#Archive

#Academic #ADME / Tox #AI / data analytics / healthtech / informatics #Automation / robotics #Business #Clinical specialities #Clinical trials #Computational chemistry #Drug development #Drug discovery #Enabling technologies #Genetics / genomes #High Content Screening #Molecular medicine #Orphan drugs #RNA #Translational #Translational chemistry

Healthcare and Life Sciences undergoing disruptive change by linked data and semantic technologies

Healthcare and Life Sciences undergoing disruptive change by linked data and semantic technologies By Hans Constandt From early days the sharing of knowledge has been one of the main forces driving science and innovation. Yet latterly, the pharmaceutical industry with its fear of loss of intellectual property… Read More

#Exclusive Content

#Academic #AI / data analytics / healthtech / informatics #Analytical chemistry #Biomarkers #Business #Cell therapy #Chemistry #Clinical specialities #Clinical trials #Computational chemistry #Drug development #Drug discovery #Drug targets #Enabling technologies #Gene editing #Gene therapy #Genetics / genomics #Genomics #Immunology #Lead discovery #Metabolomics #Molecular medicine #Oncology #Precision medicine #Preclinical #Sequencing #Stem cells

The Great Neuro-Pipeline Brain Drain – Why Big Pharma Hasn’t Given Up On CNS Disorders

The Great Neuro-Pipeline Brain Drain – Why Big Pharma Hasn’t Given Up On CNS Disorders By Julia Skripka-Serry Central Nervous System (CNS) disorders bear an economic burden of more than $2 trillion in the US and EU and rake in upwards of $80 billion a year for the… Read More

#Archive

#Academic #ADME / Tox #AI / data analytics / healthtech / informatics #Animal models #Assay development optimisation & technology #Automation / robotics #Biomarkers #Business #Chemistry #Clinical trials #Drug development #Drug discovery #High Content Screening #Imaging #Lead discovery #Lead optimisation #Medicinal chemistry #Pathology #Pharmacology #Preclinical #Regulatory #RNA #System biology #Systems biology #Target validation #Therapeutics #Toxicology #Translational #Translational chemistry

Partnering with the right CRO is a winning strategy for companies big and small

Partnering with the right CRO is a winning strategy for companies big and small By Dr Davide Molho The Bio-Pharma business model is undergoing radical changes. Over the last two decades, we have seen the biopharmaceutical industry gradually become more willing to look externally and embrace the… Read More

#Exclusive Content

#AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Business #Cellular & Molecular biology #Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Drug development #Drug discovery #High Content Screening #Immunology #Lead discovery #Mass spectrometry / NMR #Oncology #Patent Law #Pharmokinetics #Regulatory #RNA #Screening #Toxicology #Translational #Translational chemistry

Highlights from GlobalData’s CRO Benchmark Report

Highlights from GlobalData’s CRO Benchmark Report By Adam M. Dion The biopharmaceutical industry is currently facing significant headwinds. The blockbuster era is over, development costs are skyrocketing, uncertainty exists around regulatory and reimbursement, patent cliffs, generic erosion and a sluggish global economy all have industry executives losing… Read More

#Exclusive Content

#Academic #AI / data analytics / healthtech / informatics #Analysis #Animal models #Assay development optimisation & technology #Automation / robotics #Biochemistry #Business #Cell / tissue culture #Cell culture #Cellular & Molecular biology #Cellular assays #Chemistry #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Enabling technologies #Genetics / genomes #Genetics / genomics #High Content Screening #High throughput screening #Immunology #Lead discovery #Lead optimisation #Mass spectrometry / NMR #Medicinal chemistry #Oncology #Pharmacology #Pharmokinetics #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Stem cells #System biology #Systems biology #Translational #Translational chemistry

Outsourced Kinase Profiling Services: Adding Value To In-House Kinase Programmes

Outsourced Kinase Profiling Services: Adding Value To In-House Kinase Programmes Dr John Comley Biochemical kinase profiling using a large panel of kinases with a broad coverage of the human kinome has become the de facto norm within the Pharma industry. The importance of this activity is demonstrated… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Animal models #Assay development optimisation & technology #Automation / robotics #Biochemistry #Biomarkers #Business #Cell culture #Cell therapy #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Combinatorial chemistry #Computational chemistry #Drug development #Drug discovery #Drug targets #Enabling technologies #Gene therapy #Genetics / genomes #Genetics / genomics #Genomics #High Content Screening #High throughput screening #Lead discovery #Molecular medicine #Oncology #PCR #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Sequencing #Stem cells #System biology #Target validation #Therapeutics

A Decade of RNAi Screening: Too much hay and very few needles

A Decade of RNAi Screening: Too much hay and very few needles By Bhavneet Bhinder and Dr Hakim Djaballah RNAi screening is arguably the fastest growing field with the premise to better understand gene function at the genome level. It has been hailed as the second genomics… Read More

#Archive

#AI / data analytics / healthtech / informatics #Cell therapy #Cellular & Molecular biology #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Gene therapy #High Content Screening #Oncology #Pathology #Protein chemistry / Proteomics #RNA #Stem cells #System biology #Systems biology #Therapeutics

Targeting Diminished Cerebral Glucose Metabolism for Alzheimer’s Disease

Targeting Diminished Cerebral Glucose Metabolism for Alzheimer’s Disease By Dr Henderson As demographics of developed countries shift toward an older population, the number of cases of Alzheimer’s disease is anticipated to increase dramatically. Currently, there are no disease modifying treatments and approved drugs provide only symptomatic relief. Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Automation / robotics #Biochemistry #Biomarkers #Business #Cell therapy #Chemistry #Clinical specialities #Clinical trials #Computational chemistry #Drug development #Drug discovery #Gene therapy #Genetics / genomes #Genomics #High Content Screening #High throughput screening #Immunology #Lead discovery #Mass spectrometry / NMR #Medicinal chemistry #Oncology #Orphan drugs #Preclinical #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Sequencing #System biology #Systems biology #Therapeutics

Challenges and Opportunities In The Treatment Of Rare Diseases

There are approximately 7,000 rare diseases, which from a regulatory perspective are defined as those diseases where there are less than 200,000 patients in the US or that affect no more than five in 10,000 of the general population in the EU. Read More

#Archive

#ADME / Tox #AI / data analytics / healthtech / informatics #Analysis #Animal models #Assay development optimisation & technology #Automation / robotics #Biomarkers #Business #Cell / tissue culture #Cell culture #Cell therapy #Cellular & Molecular biology #Cellular assays #Clinical trials #Drug development #Drug discovery #Drug targets #Enabling technologies #Gene therapy #Genomics #High Content Screening #High throughput screening #Imaging #Lead discovery #Lead optimisation #Molecular medicine #Nanomedicine / nanotechnology #Oncology #Pathology #Pharmacology #Preclinical #Protein chemistry / Proteomics #Regenerative Medicine #Regulatory #RNA #Screening #Stem cells #System biology #Systems biology #Therapeutics #Toxicology #Translational #Translational chemistry

Realising The Genome’s Potential In The Context Of The Living Cell

Realising The Genome’s Potential In The Context Of The Living Cell By Dr Amr Abid A decade ago, with the completion of the Human Genome Project (HGP), scientists had the long-awaited sequence of the human genome in hand. Once decoded, this invaluable source of data was anticipated to… Read More

#Archive

#ADME / Tox #Analysis #Assay development optimisation & technology #Business #Cell / tissue culture #Cell culture #Cellular & Molecular biology #Cellular assays #Clinical trials #Drug development #Drug discovery #Drug targets #Genetics / genomes #High Content Screening #High throughput screening #Lead discovery #Lead optimisation #Molecular medicine #Pharmacology #Preclinical #Regulatory #RNA #Screening #Stem cells #Target validation #Toxicology

An Automated Approach To Solving Pharma’s Cardiac Toxicity Conundrum

An Automated Approach To Solving Pharma’s Cardiac Toxicity Conundrum By Dr Walter Westerink, Dr Nuria Piñeiro Costas, and Beppy van de Waart The pharmaceutical industry is facing ever-growing difficulties in developing new drugs and bringing them to market (1,2). Many factors stand in the way of R&D… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Assay development & optimisation #Assay development optimisation & technology #Automation / robotics #Biochemistry #Business #Cellular & Molecular biology #Cellular assays #Chemistry #Clinical trials #Combinatorial chemistry #Drug development #Drug discovery #Drug targets #Enabling technologies #Genetics / genomes #High Content Screening #High throughput screening #Lead discovery #Molecular medicine #Organic chemistry #PCR #Precision medicine #RNA #Screening #Stem cells #System biology #Target validation #Therapeutics #Translational #Translational chemistry

Chemical Space, High Throughput Screening and The World Of Blockbuster Drugs

Chemical Space, High Throughput Screening and The World Of Blockbuster Drugs By Dr Hakim Djaballah We are constantly told that if a high throughput screen does not identify hit(s) then blame it on the compounds in your library. The community has accepted this notion and unleashed a… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Animal models #Assay development optimisation & technology #Biomarkers #Business #Cell / tissue culture #Cell culture #Cell therapy #Cellular assays #Chemistry #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Enabling technologies #Gene editing #Gene therapy #Genetics / genomes #High Content Screening #High throughput screening #Immunology #Immunology / Virology & Vaccines #Lead discovery #Mass spectrometry / NMR #Molecular medicine #Oncology #Preclinical #Protein chemistry / Proteomics #RNA #Screening #Sequencing #Stem cells #Therapeutics

T Cell Epitope Identification By Mass Spectrometry: The Future In Detail

By Dr Nikolai Schwabe and Katherine Catchpole T cells play a crucial role in building a specialised immune response and help adapt the immune response to different challenges, whether they are intracellular bacteria, viruses or cancer or extracellular organisms such as blood-borne bacteria and… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Automation / robotics #Biomarkers #Business #Clinical trials #Computational chemistry #Drug development #Drug discovery #Enabling technologies #Genetics / genomes #Lead discovery #Mass spectrometry / NMR #Molecular medicine #Preclinical #Protein chemistry / Proteomics #Regulatory #RNA #Sequencing #Toxicology #Translational #Translational chemistry

Transforming Data Into Better Healthcare

Transforming Data Into Better Healthcare By Dr Jens Hoefkens The healthcare industry is drowning in data for which it lacks established data analysis processes. This situation exists despite the fact that appropriate and efficient data analysis processes are keys to better decision-making and enhanced healthcare therapies, which can… Read More

#Archive

#ADME / Tox #AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Business #Chemistry #Clinical trials #Drug development #Drug discovery #Isotope labelling #Lead discovery #Mass spectrometry / NMR #Medicinal chemistry #Organic chemistry #Pharmokinetics #Preclinical #Protein chemistry / Proteomics #Regulatory #RNA #Target validation

Carbon-14 Labelled API Manufacturing

Carbon-14 Labelled API Manufacturing By Dr Sean L. Kitson and Dr David Speed Carbon-14 labelled API and IMP requirements for Phase 0/I to Phase III mass balance and micro-dosing clinical trials can be met by contract manufacturing in compliance with MHRA and FDA Phase I cGMP guidelines. Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Animal models #Automation / robotics #Biologics / Biotechnology #Business #Cell culture #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Genetics / genomics #Genomics #High Content Screening #High throughput screening #Immunology / Virology & Vaccines #Protein chemistry / Proteomics #Regenerative Medicine #RNA #Screening #Sequencing #Stem cells #Target validation #Translational #Translational chemistry

Diverging Paths, Difficult Choices – Challenges Facing Pharma

Diverging Paths, Difficult Choices – Challenges Facing Pharma By Dr Steve Arlington and Dr Nick Davies Pharma is poised on a knife-edge. Major scientific and technological advances, together with socio-demographic changes, rising demand for medicines and trade liberalisation, will revive its fortunes in another decade. But in the… Read More

#Archive